全文获取类型
收费全文 | 29627篇 |
免费 | 2377篇 |
国内免费 | 1439篇 |
专业分类
耳鼻咽喉 | 346篇 |
儿科学 | 572篇 |
妇产科学 | 598篇 |
基础医学 | 5484篇 |
口腔科学 | 444篇 |
临床医学 | 2233篇 |
内科学 | 5005篇 |
皮肤病学 | 327篇 |
神经病学 | 1615篇 |
特种医学 | 549篇 |
外国民族医学 | 1篇 |
外科学 | 3008篇 |
综合类 | 4542篇 |
现状与发展 | 3篇 |
预防医学 | 1654篇 |
眼科学 | 331篇 |
药学 | 2081篇 |
3篇 | |
中国医学 | 359篇 |
肿瘤学 | 4288篇 |
出版年
2024年 | 15篇 |
2023年 | 272篇 |
2022年 | 512篇 |
2021年 | 665篇 |
2020年 | 675篇 |
2019年 | 512篇 |
2018年 | 600篇 |
2017年 | 753篇 |
2016年 | 845篇 |
2015年 | 989篇 |
2014年 | 1584篇 |
2013年 | 1706篇 |
2012年 | 1776篇 |
2011年 | 2091篇 |
2010年 | 1747篇 |
2009年 | 1781篇 |
2008年 | 2029篇 |
2007年 | 2145篇 |
2006年 | 2092篇 |
2005年 | 1985篇 |
2004年 | 1558篇 |
2003年 | 1458篇 |
2002年 | 1123篇 |
2001年 | 1000篇 |
2000年 | 836篇 |
1999年 | 678篇 |
1998年 | 462篇 |
1997年 | 434篇 |
1996年 | 219篇 |
1995年 | 238篇 |
1994年 | 164篇 |
1993年 | 113篇 |
1992年 | 68篇 |
1991年 | 54篇 |
1990年 | 42篇 |
1989年 | 45篇 |
1988年 | 40篇 |
1987年 | 20篇 |
1986年 | 23篇 |
1985年 | 19篇 |
1984年 | 16篇 |
1983年 | 8篇 |
1982年 | 15篇 |
1981年 | 10篇 |
1980年 | 8篇 |
1979年 | 3篇 |
1975年 | 2篇 |
1974年 | 3篇 |
1973年 | 2篇 |
1971年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
探究p53 基因突变与骨髓增殖性肿瘤(MPN)临床特征及预后的关系。方法 选取2017年1月~2020年1月本院收治的MPN患者126例,二代测序法检测患者p53 基因突变情况。对患者进行随访,统计患者总生存(OS)时间和累计生存率;分析p53 基因突变对患者临床特征、预后的影响。结果 126例MPN患者中12例(9.52%)检出p53基因突变,突变主要位于4~8号外显子上,不同类型患者的p53 基因突变检出率比较差异无统计学意义(P>0.05)。p53突变组患者年龄大于p53 非突变组,WBC水平低于p53 非突变组(P<0.05),两组患者的染色体核型、IPSS预后分层比较差异无统计学意义(P>0.05);p53 非突变组患者的OS时间、累计生存率均明显高于p53突变组患者(P<0.05)。结论 MPN患者p53 基因突变发生率较高,与患者年龄、WBC水平、异常核型及IPSS预后分层相关,p53 基因突变会影响患者的预后,可作为临床筛查预后不良高风险人群的客观指标。 相似文献
22.
Haonan Guo Rui Zhang Justice Afrifa Yuanyuan Wang Jingcui Yu 《Pathology, research and practice》2019,215(6):152403
PurposeWe previously demonstrated that the functional inactivation of DAL-1 and TOB1 promotes an aggressive phenotype in gastric cancer cells, but the links between both genes and the survival of patients with gastric cancer are unknown. Here, we investigated the correlations of the expression levels of DAL-1 and TOB1 with the progression of gastric cancer.MethodsA total of 270 patients who underwent resectable gastrectomy were included. The expression of DAL-1 and TOB1 was detected by immunohistochemistry.ResultsLow expression of DAL-1 in cancer tissue was significantly associated with tumor site (p < 0.05), histological grade (p < 0.01), depth of invasion (p < 0.05), lymph node metastasis status (p < 0.05), Lauren classification (p < 0.001), and clinical stage (p < 0.01). A lower level of TOB1 was observed in gastric cancer patients with diffuse type disease compared to patients with either intestinal or mixed type disease (p < 0.001). Additionally, Spearman’s correlation analysis revealed that decreased expression of DAL-1 was positively correlated with low TOB1 expression (r=0.304, p < 0.001). The survival analysis showed that low levels of DAL-1 and TOB1 were significantly associated with poor survival of gastric cancer patients (p <0.001 and p < 0.05, respectively).ConclusionThe downregulation of DAL-1 and TOB1 expression is associated with shorter survival of gastric cancer patients. Hence, DAL-1 and TOB1 may be considered potential novel markers for predicting the outcomes of patients with gastric cancer. 相似文献
23.
The pituitary tumor-transforming gene 1 (PTTG1), also known as Securin, is considered an oncogene. This study aimed to investigate the role of PTTG1 in clear cell renal cell carcinoma (ccRCC) using in silico bioinformatics approaches. A pan-cancer analysis using The Cancer Genome Atlas (TCGA) data indicated that among all cancer types copy number amplification of PTTG1 gene was most frequently found in ccRCC. However, amplification of PTTG1 gene copy number did not correlate with the increase of mRNA level in ccRCC, and did not predict the patients' overall survival. Instead, ccRCC was correlated with overexpression of PTTG1 mRNA, and its expression level was stage-dependent increased in cancer patients. An outlier analysis using the Oncomine database suggested that PTTG1 mRNA expression served as a good biomarker for ccRCC. Pathway analysis for upregulated genes enriched in PTTG1-high expressing ccRCC patients found that PTTG1 overexpression was associated with mitotic defects. Mining drug sensitivity data using the Cancer Therapeutics Response Portal (CTRP) discovered that PTTG1-high expressing ccRCC cell lines were susceptible to a Rac1 (Ras-related C3 botulinum toxin substrate 1) inhibitor NSC23766. Therefore, this study provides an in silico insight into the role of PTTG1 in ccRCC, and repurposes the Rac1 inhibitor NSC23766 for treating PTTG1-high expressing ccRCC. 相似文献
24.
25.
26.
《Clinical lung cancer》2019,20(4):e421-e429
BackgroundDetection of ALK and ROS1 gene rearrangements in non–small-cell lung cancer is required for directing patient care. Although fluorescence in situ hybridization (FISH) and immunohistochemistry have been established as gold standard methods, next-generation sequencing (NGS) platforms are called to be at least equally successful. Comparison of these methods for translation into daily use is currently under investigation.Patients and MethodsForty non–small-cell lung cancer paraffin-embedded samples with previous ALK (n = 33) and ROS1 (n = 7) FISH results were examined with the Oncomine Focus Assay and tested for ALK and ROS1 immunoreactivity. Clinical implications of concurrent molecular alterations and concordance between methods were evaluated.ResultsNGS was successful in 32 (80%) cases: 25 ALK and 7 ROS1. Few concomitant alterations were detected: 1 ALK rearranged case had an ALK p.L1196M-resistant mutation, 4 had CDK4, MYC, and/or ALK amplifications, and 1 ROS1 rearranged case showed a FGFR4 amplification. Comparison between techniques revealed 5 (16%) discordant cases that had lower progression-free survival than concordant cases: 7.6 (95% confidence interval, 2.2-13) versus 19.4 (95% confidence interval, 10.1-28.6). Remarkably, 4 of these cases had isolated 3' signal FISH pattern (P = .026).ConclusionOur data support that the identification of 3' isolated signal FISH pattern in ALK and ROS1 cases might suggest a false-positive result. NGS seems a reliable technique to assess ALK and ROS1 rearrangements, offering the advantage over immunohistochemistry of detecting other molecular alterations with potential therapeutic implications. 相似文献
27.
28.
29.
目的 检测梅州地区缺血性脑卒中患者和健康对照人群TLR4基因的(rs10759932、rs11536879、rs11536891、rs1927914)的基因多态性,经连锁不平衡分析其与缺血性脑卒中的相关性。方法 收集2018年1月1日 - 2018年7月31日住院治疗的突发缺血性脑卒中患者作为病例组,同期在体检中心收集健康人群作为对照组。应用Massarray SNP 分型技术检测两组患者TLR4基因的4个位点基因型,进行Hardy - Weinberg(H - W)平衡检测。采用不同模型分析上述位点不同基因型与脑梗死发病风险的相关性,并通过连锁不平衡分析其与缺血性脑卒中的相关性。结果 病例组纳入病例186名,对照组纳入健康人194名;4种SNP位点均符合H - W 平衡。rs1927914位点G/G基因型在对照组出现频率远远高于病例组(χ2 = 9.267,P<0.05)。rs10759932位点T/T基因型在女性对照组中出现的频率显著高于男性[OR = 0.38 (0.18 - 0.81),P<0.05]。4个SNP位点之间均存在连锁不平衡,TGCG基因型组合在缺血性卒中男性患者出现的频率显著高于女性[OR = 3.54 (1.17 - 10.69),P<0.05]。结论 梅州地区rs1927914位点A>G为保护性基因突变,可以降低缺血性脑卒中发生。4个位点的连锁不平衡与缺血性脑卒中发生存在部分性别差异,TGCG组合为男性人群的危险基因,脑卒中发生率显著升高。 相似文献
30.